Last reviewed · How we verify
Capsaicin 0.1% Cream
Activates TRPV1 receptors to reduce pain
Activates TRPV1 receptors to reduce pain Used for Pain relief for minor skin irritations.
At a glance
| Generic name | Capsaicin 0.1% Cream |
|---|---|
| Also known as | Zostrix, Capzacin |
| Sponsor | Henry Ford Health System |
| Drug class | Topical analgesic |
| Target | TRPV1 |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 2 |
Mechanism of action
Capsaicin binds to TRPV1 receptors, causing a decrease in pain perception.
Approved indications
- Pain relief for minor skin irritations
Common side effects
- Skin irritation
- Redness
- Itching
Key clinical trials
- Pain and Split-belt Motor Learning in Older Adults (NA)
- Thermosensitivity of a Topical Palmitated Formulation of Capsaicin (EARLY_PHASE1)
- Spinal and Supra-Spinal Pain Mechanisms in Patients With Fibromyalgia
- Topical Capsaicin for Cyclical Vomiting (PHASE2)
- Cervical Capsaicin for Labor Induction and Pain Relief (PHASE4)
- Chest Pain Perception and Capsaicin Sensitivity in Patients With Acute Cardiac Ischemia (NA)
- Chest Pain Perception and Capsaicin Sensitivity (NA)
- Ethnic Differences in Response to Topical Capsaicin: A Psychophysical Study on Healthy Subjects (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Capsaicin 0.1% Cream CI brief — competitive landscape report
- Capsaicin 0.1% Cream updates RSS · CI watch RSS
- Henry Ford Health System portfolio CI